al. . Tracking

Not intended for UK audiences * Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.(1)(,)(2) * Affecting up to 100,000 people in the U.S. and up to 5.6 million worldwide, PPF is linked to an underlying clinical interstitial lung disease (ILD) diagnosis, such as autoimmune ILD or hypersensitivity pneumonitis.(3)(,4,5) * PPF is the second FDA-approved indication for JASCAYD, following the recent approval for...

Ingelheim, Germany/Ridgefield, Connecticut, U.S. * Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.(1) * Approval is based on results from two clinical trials, which showed reduction in Forced Vital Capacity decline with JASCAYD versus placebo in adults with idiopathic pulmonary fibrosis (IPF).(2,3) * Nerandomilast is a new treatment option for adult patients with IPF with a well-tolerated safety profile.(2,3) Boehringer Ingelheim's...